Italia markets closed

JNJ Oct 2024 160.000 call

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
1,9000+0,3600 (+23,38%)
Alla chiusura: 01:15PM EDT
Schermo intero
Chiusura precedente1,5400
Aperto1,6400
Denaro1,4900
Domanda2,0600
Prezzo d'esercizio160,00
Scadenza2024-10-18
Min-Max giorno1,6400 - 1,9000
Contratto - Min-MaxN/D
Volume44
Open Interest993
  • GlobeNewswire

    Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®

    According to the settlement agreement, AVT04 (ustekinumab) can be marketed in the US, subject to regulatory approval, no later than February 21, 2025 REYKJAVIK, Iceland and TEL AVIV, Israel and PARSIPPANY, N.J., June 12, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA